Soltanian B, Irani S, Hashemi S, Mozhgani S H R, Ajorloo M, Cheraghi Y et al . Mycoplasma contamination in cell cultures treated with ciprofloxacin and enrofloxacin: brief report. Tehran Univ Med J 2015; 72 (11) :794-798
URL:
http://tumj.tums.ac.ir/article-1-6509-en.html
1- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
2- Human Rabies Vaccine Laboratory, Pasteurs Production and Research Complex, Institute of Iran, Tehran, Iran.
3- Human Rabies Vaccine Laboratory, Pasteurs Production and Research Complex, Institute of Iran, Tehran, Iran. Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Recombinant Hepatitis B Vaccine Production, Pasteurs Production and Research Complex, Institute of Iran, Tehran, Iran.
5- Human Rabies Vaccine Laboratory, Pasteurs Production and Research Complex, Institute of Iran, Tehran, Iran. WHO CC For Reference and Research on Rabies, Pasteur Institute of Iran, Tehran, Iran. , agholami@pasteur.ac.ir
Abstract: (11488 Views)
Background: Mycoplasma contamination in cell cultures is considered as a major economic, research and production problem. In this study, mycoplasma-infected Vero cell lines were treated by various dilutions of ciprofloxacin and enrofloxacin in a timely manner. Removal of mycoplasma contamination from infected cell cultures was evaluated and demonstrated by polymerase chain reaction (PCR) method.
Methods: This study was done from October 2013 to May 2014, in Human Rabies Vaccine Laboratory, Pasteur Institute Production and Research Complex, Tehran, Iran. Different dilutions of ciprofloxacin and enrofloxacin were used in sequential passages for treatment of infected Vero cell line. Based on lowest passages of the cell line, antibiotic treatment with ciprofloxacin and enrofloxacin was done. Amelioration of the infection and removal of mycoplasma contamination was confirmed in each step by PCR method. The technique for order of preference by similarity to ideal solution, TOPSIS method, was used to suggest the most efficient concentration of ciprofloxacin and enrofloxacin.
Results: Proposed concentration of ciprofloxacin is 20 μg/ml, and in the second order is 200 μg/ml. For enrofloxacin the best proposed concentrations are 30, 300 and 3 μg/ml respectively. Ciprofloxacin and enrofloxacin and ability of them for removal of mycoplasma and also the time of treatment were verified by evaluation of the recurrence of infection through consecutive subcultures of the treated cell line.
Conclusion: Our results showed that 20 μg/ml of ciprofloxacin was the dilution of choice for mycoplasma elimination followed by 200 μg/ml of ciprofloxacin. Concentrations of 3, 30 and 300 of enrofloxacin, respectively, are appropriate for mycoplasma removal. More detailed works would be needed to verify the authenticity of the proposed simple and affordable way of mycoplasma elimination.
Type of Study:
Brief Report |